학술논문
Endovascular Treatment in Patients With Acute Ischemic Stroke and Comorbid Cancer: Analysis of the Italian Registry of Endovascular Treatment in Acute Stroke
Document Type
article
Author
Federica Letteri; Giovanni Pracucci; Valentina Saia; Fabrizio Sallustio; Alfredo Paolo Mascolo; Valerio Da Ros; Rossana Tassi; Maurizio Acampa; Sandra Bracco; Alessandro De Vito; Ilaria Casetta; Andrea Saletti; Guido Bigliardi; Stefano Vallone; Marta Iacobucci; Patrizia Nencini; Vanessa Palumbo; Sergio Nappini; Laura Malfatto; Cinzia Finocchi; Lucio Castellan; Simona Sacco; Nicola Giannini; Guido Andrea Lazzarotti; Roberto Cavallo; Chiara Comelli; Adriana Critelli; Nicola Cavasin; Simona Marcheselli; Nunzio Paolo Nuzzi; Mauro Magoni; Roberto Gasparotti; Paolo Invernizzi; Marco Pavia; Angelica Tinelli; Nicola Burdi; Tiziana Tassinari; Riccardo Padolecchia; Marco Petruzzellis; Luigi Chiumarulo; Maria Valeria Saddi; Giovanni Dui; Monia Russo; Pietro Amistà; Andrea Zini; Salvatore Mangiafico; Danilo Toni
Source
Stroke: Vascular and Interventional Neurology, Vol 3, Iss 3 (2023)
Subject
Language
English
ISSN
2694-5746
Abstract
Background Acute stroke patients with comorbid cancer (CC) are more preferably addressed with endovascular treatment (EVT) than thrombolytic therapy, due to the presumed potential risk of hemorrhagic transformation and systemic bleeding. This study aims to evaluate clinical and procedural outcomes of acute stroke patients with CC receiving EVT. Methods Using the Italian Registry of Endovascular Treatment in Acute Stroke, we reviewed prospectively collected data of CC patients treated with EVT from 2011 to 2017. Outcome measures were modified Thrombolysis in Cerebral Infarction score, symptomatic intracranial hemorrhage rate, and 3‐month modified Rankin scale. We also compared CC patients with a control group without cancer (non‐comorbid cancer) receiving EVT and matched the 2 populations with a 1:1 propensity score. Results Out of 4598 stroke patients treated with EVT, 165 (3.6%) had a CC. Modified Thrombolysis in Cerebral Infarction 2b‐3 was obtained in 73.8% of CC and 74.5% of non‐comorbid cancer patients (P=0.84), whereas the rate of symptomatic intracranial hemorrhage rate was 8.2% and 6.9%, respectively. Three‐month all‐cause mortality was 33.3% in CC patients and 18.6% non‐comorbid cancer patients (P